BNET Industries
Market Cap:$3.0M
Last Fiscal Year Sales:$19.2M
- Public
- US
Dow Jones Description
Mfr, Developer & Marketer of Veterinary Diagnostics, Vaccines & Other Animal Health Related Products
President and CEO
Paul R. HaysNumber of Employees 100
Contact Information
12200 NW Ambassador Dr Ste 101
Kansas City, Missouri 64163
(858) 464-3500
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
News & Analysis
Filter by
sales and synbiotics corp. - All News and Analysis
Synbiotics Corporation Announces Approval of Witness Canine Heartworm Test
SAN DIEGO--BUSINESS WIRE--July 28, 1998--Synbiotics Corporation (NASDAQ:SBIO) announced today that it has obtained U.S. Department of Agriculture approval to market WitnessrHW in the United States, the fastest and easiest to use product yet developed for the diagnosis of canine heartworm.WitnessrHW represents the latest Synbiotics innovation in easy-to-use diagnostic products for...
Synbiotics Corp. reports results for fiscal 1995; ICT GOLD HW diagnostic test drives revenue growth
SAN DIEGO--BUSINESS WIRE--March 29, 1996--Synbiotics Corp. (NASDAQ:SBIO) Friday reported revenues of $14.1 million for the year ended Dec. 31, 1995 versus $12.1 million for the prior 12 month period, an increase of 17%.The company also reported net income of $501,000 or 9 cents per share for 1995, compared to a...
Synbiotics posts modest profit; offering awaits SEC's approval
Synbiotics posts modest profit; offering awaits SEC's approval Synbiotics Corp. finds itself in its strongest financial position ever while awaiting approval from the Securities and Exchange Commission for a public offering of 1.25 million shares of common stock. Revenues for the San Diego biomedical company for the year...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Paul R. Hays | President and CEO |
| Keith A. Butler | Cfo |
| B. Kent Luther | Vice President, Sales & Marketing |
| Chinta Lamichhane | Vice President, R & D |
| Clifford Frank | Vice President, Strategic Projects |
| Michael Harrod | Director of Technical Resources |
| Christophe Calleja | Marketing Manager |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald E Phillips | Chairman of the Board of Directors |
| Christopher P. Hendy | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | President and CEO | Current |
| Synbiotics Europe S.A.S. | President | Current |
| Synbiotics Corporation | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Cfo | Current |
| Synbiotics Corporation | Vice President | Current |
| Synbiotics Corporation | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, Sales & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, R & D | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, Strategic Projects | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Director of Technical Resources | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Marketing Manager | Current |
| Organization | Position | Status |
|---|---|---|
| Finds Ammonia | Current | |
| Synbiotics Corporation | Chairman of the Board of Directors | Current |
| Mississippi.Com | President | Former |
| Organization | Position | Status |
|---|---|---|
| Redwood Holdings, Inc. | Current | |
| Schonstedt Instrument Company | Board of Directors | Current |
| Synbiotics Corporation | Board of Directors | Current |
| Marine Midland Bank | Former | |
| Xavier University | B.S. Degree In Business Administration | Former |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes


